Casi announces first patient dosed in phase 1/2 clinical trial of cid-103 in immune thrombocytopenia

Beijing, china / accesswire / january 6, 2025 / casi pharmaceuticals, inc. (nasdaq:casi), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the first patient has been dosed in the phase 1/2 trial to evaluate the safety and tolerability of cid-103 in adult patients with chronic immune thrombocytopenia (itp) in china. "dosing the first patient in our phase 1/2 study marks a significant milestone for both cid-103 program and chronic itp patients who have limited treatment options," said dr. wei-wu he, chairman and ceo of casi, "the rapid execution underscores our commitment to accelerating clinical development.
CASI Ratings Summary
CASI Quant Ranking